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Abstract
In this research, an effort has been done for the development of effervescent
controlled release floating tablet (ECRFT) from solid dispersions (SDs) of
diclofenac sodium (DS) for upsurge the solubility and dissolution rate. ECRFT of
DS was prepared by using SDs of DS and its SDs prepared with PEG as carrier using
thermal method (simple fusion). SDs of DS was formulated in many ratios (1:1, 1:2,
1:3 and 1:4). Prepared SDs were optimised for its solubility, % drug content and %
dissolution studies. Tablets were formulated by using optimised SDs products and
all formulation was evaluated for various parameters. A clear rise in dissolution rate
was detected with entirely SD, amid that the optimised SD (SD4) was considered
for ECRFT. Among all the tablet formulations, its F3 formulation was better in all
the terms of pre-compression and post-compression parameters. It had all the
qualities of a good ECRFT, based on this F3 formulation was selected as the best
formulation. Data of in vitro release were fitted in several kinetics models to explain
release mechanism. The F3 formulation shows zero order release. From this study,
we can conclude that ECRFT containing SDs of DS can be successfully used for
achieving better therapeutic objective.
Keywords: solid dispersion, diclofenac sodium, polyethylene glycol,
dissolution enhancement, floating tablets
1. Introduction
Diclofenac sodium (DS) is an effective NSAID with high affinity for both COX-1
and COX-2 receptors and it is one and only maximum frequently recommended
drugs in India for the cure of pain, inflammation and joint stiffness caused by
arthritis. According to BCS classification system DS belonging from class II means
to say having poor solubility and poor dissolution rate [1] hence the focus of this
study was on converting BCS class from II to I by increasing its solubility and
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dissolution rate of DS Which was taken as model drug [2]. The release rate can be
improved by increasing surface area of existing drug by using several techniques
but among these methods solid dispersion technique is one of the best techniques
for increasing the surface area [3]. Hence, an effort was made to increase the
dissolution characteristics using the solid dispersion technique [3, 4]. It has absorp-
tion site in upper part of gastro intestinal tract. Gastric retention of DS was very
short that is why the bioavailability of drug is 54% which is very low because near
about 50% portion of orally given drug misses the absorption window. The phar-
macokinetic profile of DS showed that the half-life is about 1.2–2 h and hence
there is a requirement of frequent dosing (3–4 tablets daily) [5] but this require-
ment of frequent dose is very dangerous for patients because due to this frequent
dosing fluctuation in plasma drug level in body and need constant monitoring of
patient for adjustment of dose regimen. That is why this reason may consequently
support faster absorption of drug in stomach with higher concentrations for bio-
availability improvement. Therefore in order to improve drug dissolution and
reduced dosing frequency, it was attempted to formulate solid dispersion of DS
[6, 7] and then develop effervescent controlled release floating tablet [8]. The
emphasis of the current research was to increase the release rate and bioavailability
of DS through preparing ECRFT (effervescent control release floating tablets) with
dual approach [9] using solid dispersion product of DS in order to regulate the drug
release and make available security from first pass metabolism.
2. Methodologies
2.1 Preformulation studies
Prior to the development of dosage forms, it is essential that certain fundamen-
tal, physical and chemical properties of the drug molecule and other derived prop-
erties of the drug powder are determined and should be considered in the
formulation in relation to the proposed dosage form and route of administration.
These studies should focus on those physiochemical properties of the drug that
could affect drug performance and development of an efficacious dosage form.
A typical preformulation program should begin with the description of the
organoleptic qualities of the drug substance. The colour, odour and taste are of
immense value in developing an aesthetically acceptable formulation.
2.1.1 Identification and characterisation of diclofenac sodium
2.1.1.1 Physical appearance
Drug sample has been noted for its organoleptic properties. The drug is white to
slightly yellowish crystalline powder, odour: slight and characteristic [1]. Drug was
received as gift sample (15 g) from Kwality Pharmaceuticals Ltd., Amritsar.
2.1.1.2 Melting point determination
The melting point of compound is the temperature at which it changes from a
solid to liquid [10]. This is a physical property often used to identify compounds.
2.1.1.2.1 Procedure
a. A capillary melting tube was taken.
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b. A small amount of compound was placed on a clean surface. The compound
was put in to open end of capillary tube.
c. The capillary melting point tube was placed in melting point apparatus
(Macro scientific works).The sample was observed continuously, so that the
melting point of the sample was not missed. Slow heating was done for most
accurate results. The melting range was recorded which beings when the
sample first starts to melt and ends when the sample completely melted.
2.1.1.3 Solubility studies
Solubility may be defined as the spontaneous interaction of two or more sub-
stances to form a homogeneous dispersion [11]. The solubility of diclofenac sodium
was studied in various aqueous and non-aqueous solvents. About 10 mg of drug was
taken in 10 ml of each solvent at room temperature in screw-capped test tubes and
shaken for 30 min in a sonicator. The solubility was checked by U-V spectroscopy in
all cases and reported in Table 1.
2.1.1.4 U.V. spectrophotometer
The organic molecule in solution when exposed to light in the ultra-violet region
of the spectrum, absorbed light of particular wavelength depending on the type of
electronic transition associated with absorption [12].
2.1.1.4.1 Diclofenac sodium
The solution (10 μg) of diclofenac sodium was prepared in simulated gastric
fluid pH 1.2 and scanned spectrophotometrically (Systronics, Double beam UV-VIS
Spectrophotometer: 2201). The scanning range was in between 200 nm to 400 nm.






Bulk Density 0.56 gm/ml
True Density 0.64 gm/ml
Carr’s Index 14.28%
Hausner’s Ratio 1.14
Melting Point STD: 280°C
OBS: 282–283°C
Solubility Sparingly soluble: Water
Freely soluble: methanol
Soluble: 0.1 N HCl
Insoluble: ether, chloroform and toluene
Partition coefficient 1.25
Table 1.
Preformulation characters of diclofenac sodium.
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determined λmax, 276 nm (Figure 1) was similar as reported in the literature
(276 nm).
2.1.1.5 I.R. spectrophotometry
About 1 mg of the sample and 100 mg of the potassium bromide (KBr) was
taken in a mortar and triturated [13]. A small amount of triturated sample was
taken into a pellet maker and compressed at 10 kg/cm2. The pellet was kept onto the
sample holder and scanned from 4000 to 400 cm1.The I-R spectrum of drug
sample was obtained using FTIR-8400 s, shimadzu. Important peaks are reported in
Table 2 and graphically represented in Figures 2, 3. This I-R spectrum was found
concordant with the IR of diclofenac sodium reported in the official monograph.
2.1.1.6 Quantitative estimation of drug
For the present study the spectrophotometric method given in the official books
was selected for its sensitivity, specificity, simplicity, reproducibility, rapidity and
accuracy [14].
2.1.1.7 Preparation of calibration curve of diclofenc sodium in simulated gastric fluid
(pH 1.2)
Accurately weighed 50 mg of drug (diclofenac sodium) was dissolved in 100 ml
of simulated gastric fluid pH 1.2 to give a solution of 500 μg/ml concentration and
Figure 1.
U.V. scan of diclofenac sodium in simulated gastric fluid (PH 1.2).
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Characteristic peaks of diclofenac sodium.
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this was served as a standard solution [15, 16]. From this solution 10 ml was taken
and diluted to 100 ml using simulated gastric fluid pH 1.2 to get a solution of 50 μg/
ml concentration and this solution was served as the standard solution. In to a series
of 10 ml volumetric flasks, aliquots of standard solution (i.e. 0.4, 0.8, 1.2, 1.6, 2.0,
3.0, 4.0, 5.0, 6.0 ml) were added and made up the volume up to 10 ml using
simulated gastric fluid pH 1.2. The absorbance of these solutions was measured
against reagent blank at 276 nm (Table 3). A standard curve between concentration
and absorbance was plotted (Figure 4). A straight line passing through origin is
obtained.
2.1.1.8 Partition coefficient
The partition coefficient directly influences the permeability of drug through
various membranes [17–19]. The study has been designed to determine partition
coefficient of drug in 1-octanol and pH 1.2 solutions. The partition coefficient
between 1-octanol and Simulated gastric fluid (pH 1.2) was determined by shake
flask method. About 10 mg of drug was dissolved in one of the phases, and is shaken
with the other partitioning solvent for 30 min, allowed to stand for 5 min and then
majority of the lower aqueous phase was run off. The drug concentration in both the
Figure 2.
FTIR spectroscopy of pure diclofenac sodium.
Figure 3.
I-R spectra of pure diclofenac sodium from I.P. 1996.
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aqueous and 1-octanol phases was determined spectrophotometrically at 276 nm
and calculated the partition coefficient. The partition coefficient was found
to be 1.25.
Partition Coefficient ¼ Conc:of drug in oil phase=Conc:of drug in aqueous phase
(1)
2.1.2 Result and discussion
Samples of diclofenac sodium obtained as a gift sample from kwality pharma-
ceuticals pvt. Ltd., Amritsar was identified and characterised as per the identifica-
tion test given in official monograph. Physical appearance and melting point of the
drug sample under investigation was found to be same as that of the official reports.
The results are given in Table 4. The solubility of diclofenac sodium was deter-
mined in aqueous and non-aqueous solvents. Diclofenac sodium was found to be
soluble in 0.1NHCl and ethanol; sparingly soluble in water, practically insoluble in
ether, chloroform and toluene. Partition coefficient of the drug was found to be
1.25.The results are given in Table 1.
S. No Concentration (μg/ml) Abs(λmax-276 nm) (mean  SD)
1 0 0.000  0.00
2 2 0.068  0.002
3 4 0.128  0.005
4 6 0.190  0.0015
5 8 0.246  0.0021
6 10 0.315  0.0022
7 12 0.329  0.004
8 14 0.401  0.001
9 16 0.445  0.0032
10 18 0.522  0.0051
11 20 0.589  0.0059
Table 3.
Data for calibration curve of diclofenc sodium in simulated gastric fluid pH 1.2 at 276 nm (n = 3).
Figure 4.
Calibration curve of diclofenac sodium in pH 1.2 at 276 nm.
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The drug was identified by IR spectroscopy and the characteristic peaks
obtained (Figure 2) compared with standard spectra (Figure 3) of pure drug
reported in official monograph (IP1996). The IR spectra of drug sample are in
agreement with the standard IR spectra of pure diclofenac sodium given in official
monograph [1]. Important peaks are reported in Table 2.
In the present study, a reported U-V spectrophometric method was used for the
estimation of diclofenac sodium. The calibration curve of diclofenac sodium was
prepared in simulated gastric fluid pH 1.2. The data was regressed to obtain straight
line. The correlation coefficient was found to be 0.996 in simulated gastric fluid
pH 1.2 indicating good linearity. The calibration curve was found to obey Beer-
Lamberts Law in the concentration range studied (0–20 μg/ml).
3. Materials
Diclofenac Sodium (Batch no. A5/206), hydroxyl propyl methyl cellulose
(HPMC) K100M (Batch no. HP121406 MC) and crosspovidone (Batch no.
YPVPP09319040) were obtained from kwality pharmaceutical pvt ltd Amritsar, as
gift samples. Sodium bicarbonate (NaHCO3), citric acid, polyvinyl pyrrolidone
(PVP K-30), magnesium stearate, lactose and Isopropyl alcohol were purchased
from local suppliers. Marketed product, “Voveran SR100 or Voveran 50”,
(Manufactured by Ranbaxy, India; Batch no.131003 AU or 320,028), used for
comparative studies, was purchased from the local retail pharmacy.
4. Methods
4.1 Preparation of physical mixtures (PM)
Physical mixtures were prepared by mixing the appropriate amounts of the drug
and carrier (PEG 6000) in the different weight ratios of 1:1, 1:2, 1:3 and 1:4 in
mortar [3, 4, 6, 7]. The resulting mixtures were sieved through sieve no. 80,
collected and stored in closed container away from light and humidity until use.
4.2 Preparation of solid dispersion
Melt method was used to prepare solid dispersions of diclofenac sodium with
PEG 6000 containing different weight ratio (1:1, 1:2, 1:3, 1:4, and 1:5) (Table 5).
Diclofenac sodium and PEG 6000 were weighed according to their weighed ratios.
PEG 6000 was melted at 60°C. In this melted PEG 6000, diclofenac sodium was
added. It was mixed well and flashed cooled on an ice bath and then stored over-
night in desiccators. The prepared solid dispersion was then grounded by using a
mortar and pestle, sieved through a mesh no. 40 and stored over a fused calcium
chloride in a desiccators’ for further use.
S. No Melting ranges Melting point (mean  SD)
1 288–290°C 289.12  0.21
Table 4.
Melting point result of diclofenac sodium.
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4.3 Characterisation of solid dispersion/ physical mixtures of diclofenac
sodium with PEG-6000SDs
4.3.1 FTIR spectroscopy
FTIR spectra of drug, PEG 6000 and solid dispersion of DS were obtained.
About 1 mg of sample was mixed thoroughly with 100 mg potassium bromide IR
powder and compacted under vacuum at a pressure of about 12 psi for 3 min. The
resultant disc was mounted in a suitable holder in perkin elmer USA spectrum 65 IR
spectrophotometer and the IR spectrum was recorded from 4000 to 400 cm1 in a
scan time of 12 min [20]. The resultant spectra were compared for any spectral
changes. Figure 5 shows the FTIR spectra of the (i) drug, (ii) carrier and (iii)
Surface solid dispersion. There was no significant change in the spectrum of solid
dispersions, as incorporation of diclofenac into the carrier (PEG6000) did not
modify the position of its functional groups.
4.3.2 Determination of saturation solubility
Saturation solubility was determined by using shake flask method [20]. Excess
quantities of pure DS, prepared SDs and PMs were added in 25 ml distilled water in







Composition of solid dispersion and there assign batch code.
Figure 5.
Comparative FTIR spectra of diclofenac, PEG6000, & solid dispersion of diclofenac with PEG6000.
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conical flasks which were then put in orbital shaker at 37°C and at 100 rpm for 72 h.
Absorbance of resulting solution was measured on UV/Visible spectrophotometer
(UV-1800 Shimadzu, Japan) at 276 nm.
4.3.3 Determination of pH dependent solubility
Shake flask method same as that for saturation solubility [20] was used with
0.1 N HCl.
4.3.4 Percent drug content
SDs equivalent to 50 mg of diclofenac sodium were weighed accurately and
dissolved in 50 ml of ethanol by using mechanical shaker for 30 min. The solutions
were filtered using whatman filter paper and drug content was determined by
measuring absorbance at 276 nm by UV/visible spectrophotometer [6, 20]. From
above evaluation tests, optimised formulation was confirmed (SD4 in Table 6)
which was then subjected to in vitro dissolution studies.
4.3.5 In vitro dissolution studies
In vitro dissolution studies of prepared SDs were carried out in 900 ml of 0.1 N
HCl as a medium using USP type 2 test apparatus with three replicates. The paddle
rotation speed was 75 rpm and a temperature of 37°C  0.5 was maintained. In all
experiments, 5 ml of dissolution sample was withdrawn at 5 min interval, filtered
using a 0.45-mm Whatman filter, and replaced with an equal volume of fresh
medium to maintain a constant total volume. Samples were analysed on UV/Visible
spectrophotometer at 276 nm.
4.4 Results and discussions
IR study was carried out to check the compatibility between the selected Poly-
mers, with the drug. When the spectra were compared it was found that there was
no shifting of functional peaks and no overlapping of characteristic peaks and also
there was no appearance of new peaks. Figure 5 shows the IR spectra of various
samples. No significant change in the IR spectra of diclofenac sodium complexes
was obtained, except for the broadening of the peaks. The broadening of peaks may




0.1 N HCl (mg/ml)
pH dependent solubility in
0.1 N HCl (mg/ml)
Percent drug
content (in 50 mg)
Pure DS 0.3886  0.0044 6.020  0.038 —
PM1 (1:1) 0.4481  0.0045 8.328  0.069 82.75  1.54
PM2 (1:2) 0.4603  0.0073 9.765  0.0073 86.68  1.27
PM3 (1:3) 0.5168  0.0034 10.278  0.086 88.01  0.94
PM4 (1:4) 0.5947  0.0046 11.265  0.101 90.92  1.44
SD1 (1:1) 1.1802  0.0136 11.984  0.064 93.87  1.89
SD2 (1:2) 1.2612  0.0097 12.735  0.028 94.50  2.11
SD3 (1:3) 1.4894  0.0036 13.324  0.071 95.16  1.34
SD4 (1:4) 1.9261  0.0154 14.291  0.144 96.72  1.53
Table 6.
Saturation solubility, pH dependent solubility and percent drug content studies of pure DS, SDs and PMs.
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molecule. Various SDs of DS were prepared using PEG-6000, as carriers by thermal
method (Simple fusion) technique to increase the solubility as well as dissolution of
poorly aqueous soluble drug DS. The prepared SDs and PMs of DS were evaluated
for saturation solubility, pH dependent solubility; percent drug content and in vitro
dissolution studies. The saturation solubility and pH dependent solubility of pure
DS, various prepared SDs and PMs of DS in 0.1 N HCl were measured and the
results are given in Table 6. All PMs showed higher saturation solubility as com-
pared with pure DS. Again, SDs of DS showed higher saturation solubility than their
respective PMs of DS and carrier. This might be attributable to an improvement of
wetting of drug particles and localised solubilisation by the hydrophilic polymeric
carriers.
Based on the saturation solubility, pH dependent solubility in 0.1 N HCl and
drug content among the 8 formulations, PM4 and SD4 were selected to carry out
in vitro dissolution study and were compared with that of pure DS. The in vitro
dissolution study of the pure DS, SD4 and PM4 using PEG-6000 as carrier was
carried out in 0.1 N HCl at 37°C 1°C for 60 min and it was examined by plotting %
drug dissolved against a function of time (Figure 6). SD4 and PM4 showed
improved dissolution of DS over that of pure DS. Pure DS alone yields the slowest
dissolution with only 35.65% drug and the dissolution of PM4 (70.76%) was found
to be significantly faster when compared with pure DS. SD4 showed the fastest
dissolution (92.99%) than PM4 and pure DS. This observation (Table 7) indicated
that the increased dissolution of DS from SD4 due to presence of drug in amorphous
state as compared PM4 and pure DS. As the proportion of PEG-6000 increased,
dissolution rates have also been increased. The improvement of dissolution may
be due to its hydrophilic nature of the carrier. Thus it can be concluded that the
solubility of the poorly soluble drug, DS can be improved markedly by using
solid dispersion technique and the carrier, PEG-6000 has increased the dissolution
of the drug.
Figure 6.
Dissolution of the pure DS, SD4 and PM4.
Percentage of diclofenac sodium dissolved from
Time in min/formulation code 10 15 30 45 60
Pure DS 3.37 8.50 14.35 18.85 35.65
PM4 6.67 21.23 39.44 59.41 70.76
SD4 9.73 30.51 52.25 74.00 92.99
Table 7.
Dissolution of the pure DS, SD4 and PM4.
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4.5 Preparation of floating gastro retentive tablets
Various ratios of solid dispersions of diclofenac sodium with PEG-6000 were
evaluated for percent drug content and out of them the best ratio was selected for
preparation of floating tablet of diclofenac sodium. Tablets were prepared by con-
ventional wet granulation method using HPMC K4M, HPMC K15M as a release
retardant, carbopol as a swelling agents and NaHCO3 as gas generating agent. Citric
acid was also incorporated in the formulation to provide sufficiently acidic medium
for NaHCO3 to react and maintain buoyancy. The composition of various formula-
tions is given in Table 8. All ingredients (except gas generating agents and magne-
sium stearate) were passed through sieve no. 60 and mixed in a polybag for 10 min
and granulated using PVP K30 (in isopropyl alcohol). The wet mass was passed
through sieve number 14 and dried in hot air oven at 50°C for 1.5 h. Dried granules
were mixed with magnesium stearate as lubricant, talc as glidant and compressed
using 16-station rotary tablet press (Rimek Minipress-I, India) using 13 mm flat
punch in order to obtain controlled release floating gastro retentive tablets
containing 50 mg of diclofenac sodium. Prior to compression, granules were evalu-
ated for their flow and compressibility characteristic.
4.6 Characterisation of granules
4.6.1 Drug-polymer interaction studies
To study the interaction between drug and polymer, interaction study were
performed, drug polymer study were carried out according to the following proce-
dure. Drug and polymer were mixed in 1:1 ratio and put into the glass vials. The
glass vials were sealed and placed in the stability chamber at 40°C and 75% RH for
21 days. The sample was analysed for colour change, liquification and bad odours
after 7, 15 and 21 days. The IR spectra were taken after 21 days and analysed for any
shift in major peaks. No shift was observed in the IR spectrum and no additional
peak observed indicating no interaction between drug and polymer.
Ingredient (mg) Formulation code
F1 F2 F3 F4 F5 F6
SD4 (solid dispersion of diclofenac sodium) 250 250 250 250 250 250
HPMC K4 70 — 93 — 105 —
HPMC K15M — 70 — 93 — 105
Carbopol 934P 70 70 47 47 105 105
Sodium bicarbonate 45 45 45 45 65 65
Citric acid 30 30 30 30 40 40
Avicel PH 102 50 50 50 50 50 50
Magnesium stearate 5 5 5 5 5 5
PVP K-30 5% PVP IN IPA
Total weight 520 520 520 520 620 620
Table 8.
Composition of different formulations of diclofenac sodium floating tablets.
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4.6.2 I-R spectrum of pure drug
About 1 mg of the sample and 100 mg of the potassium bromide (KBr) was
taken in a mortar and triturated. A small amount of triturated sample was taken into
a pellet maker and compressed at 10 kg/cm2. The pellet was kept onto the sample
holder and scanned from 4000 to 400 cm1.The I-R spectrum of drug sample was
obtained using FTIR-8400 s, Shimadzu (Figure 2).
4.6.3 I-R spectra for diclofenac sodium with HPMC K4M + HPMC K15M and carbopol
934P
Sample mixture of diclofenac sodium with HPMC K4M + HPMC K15M and
carbopol 934P were prepared in KBr discs (1 mg sample in 100 mg KBr). A small
amount of triturated sample was taken into a pellet maker and was compressed at
10 kg/cm2. The scanning range was 4000–400 cm1, and the resolution was 4 cm1
(Figures 7 and 8).
4.7 Evaluation of granules properties
4.7.1 Angle of repose
The angle of repose of was determined by the funnel method. The accurately
weighed granules were taken in a funnel. The height of the funnel was adjusted in
such a way that the tip of the funnel just touched the apex of the heap of the
granules. The granules were allowed to flow through the funnel freely onto the
surface [9, 21]. The diameter of the powder cone was measured and angle of repose
was calculated using the following equation.
θ ¼ tan –1 h=rð Þ (2)
where, h and r are the height and radius of the powder pile, respectively.
4.7.2 Bulk density
Both bulk density (BD) and tapped bulk density (TBD) were determined. A
quantity of 2 g of powder from each formula, previously lightly shaken to break any
Figure 7.
FTIR of diclofenac sodium + HPMC K4M + HPMC K15M.
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agglomerates formed, was introduced into a 10 ml measuring cylinder [9]. After the
initial volume was observed, the cylinder was allowed to fall under its own weight
on to a hard surface from the height of 2.5 cm at 2 s intervals. The tapping was
continued until no further change in volume was noted.
BD and TBD were calculated using the following formulas.
BD ¼ Weight of the Powder=Volume of the packing: (3)
TBD ¼ Weight of the powder=Tapped volume of the packing: (4)
4.7.3 Compressibility index/carr’s index
The flow property was also determined by measuring the compressibility index.
It is an important measure that can be obtained from the BD and TBD. According to
the theory, the less compressible materials are more flowable. A material having
values of less than 20–30% is defined as the free flowing material [9, 21]. Based on
the BD and TBD, the percentage compressibility of the bulk drug was determined





4.8 Evaluation of floating tablets
4.8.1 In vitro buoyancy determination studies
In vitro buoyancy studies were performed for all the formulations as per the
method described by Rosa et al [22]. The randomly selected tablets from each for-
mulation were kept in a 100 ml beaker containing simulated gastric fluid, pH 1.2 as
per USP. The time taken for the tablet to rise to the surface and float was taken as
floating lag time (FLT). The duration of time the dosage form constantly remained on
the surface of medium was determined as the total floating time (TFT) [9, 23–25].
4.8.2 General characteristic
The formulated tablets were assessed for its general appearance.
Figure 8.
FTIR of diclofenac sodium + carbopol 934P.
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4.8.2.1 Thickness and diameter
Thickness and diameter of tablets was determined using vernier calliper. Three
tablets from each batch were used, and average values were calculated.
4.8.2.2 Weight variation
Formulated floating tablets were tested for weight uniformity, 20 tablets were
weighed collectively and individually. From the collective weight, average weight
was calculated. Each tablet weight was then compared with average weight to
ascertain whether it is within permissible limits or not.
4.8.2.3 Friability test
The Roche friability test apparatus was used to determine the friability of the
tablets. 20 pre-weighed tablets were placed in the apparatus, which was given 100
revolutions, after which the tablets were reweighed. The percentage friability was
calculated.
%F ¼ 1 loss in weight=initial weightð Þf g  100 (6)
4.8.2.4 Hardness test
Hardness of the tablet was determined using the monsanto hardness tester. The
lower plunger was placed in contact with the tablet and a zero reading was taken.
The plunger was then forced against a spring by tuning a threaded bolt until the
tablet fractured. As the spring was compressed a pointer rides along a gauge in the
barrel to indicate the force.
4.8.2.5 Percent drug content
Ten tablets were weighed and powdered. An amount of the powder equivalent
to 50 mg of diclofenac sodium was dissolved in 100 ml of 0.1 N HCl, filtered,
diluted suitably and analysed for drug content at 276 nm using UV/Visible
spectrophotometer.
4.8.2.6 Determination of percent swelling index (percentage water uptake)
The swelling properties of floating tablet containing drug were determined by
placing the tablet matrices in the dissolution test apparatus, in 900 ml of distilled
water at 37°C  0.5°C paddle rotated at 50 rpm. The tablets were removed period-
ically from dissolution medium. After draining free from water by blotting paper,
these were measured for weight gain. Swelling characteristics were expressed in
terms of percentage water uptake (%WU) according to the equation shows rela-
tionship between swelling index and time.
WU% ¼
Weight of swollen tablet–Initial weight of the tablet
Initial weight of the tablet
 100 (7)
4.8.2.7 Dissolution studies using USP type II apparatus with wire sinker
Dissolution test was carried out using USP type II apparatus with wire sinker.
The drug release study was carried out for 12 hr. in 900 ml of 0.1 N HCl dissolution
14
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media, maintained at 37°C 0.5°C and agitated at 50 rpm. Periodically 5 ml samples
were withdrawn and filtered through whatman filter paper and samples were
replaced by its equivalent volume of dissolution media. The absorbance of DS was
measured UV/Visible spectrophotometrically at 276 nm. The percentage cumulative
drug release was calculated and amount of CP released from tablets was deter-
mined. The floating tablet is wound with the helical wire sinker.
4.8.2.8 Kinetic of drug release
The result of in vitro dissolution studies of tablet were fitted with various kinet-
ics models, like zero order (% cumulative drug release vs. time), first order (log %
drug remaining vs. time), Higuchi’s model (% cumulative drug release vs. square
root of time) but these models failed to explain drug release mechanism due to
swelling (upon hydration) along with gradual erosion of the matrix. Therefore the
dissolution data were also fitted to well-known Korsmeyer and Peppas semi-
empirical model to ascertain the mechanism of drug release.
log Mt=M∞ð Þ ¼ logkþ n logt (8)
Where, M∞ is the amount of drug release after infinite time; k is the release rate
constant which considers structural and geometric characteristics of the tablets; and
n is the diffusional exponent; indicative of the mechanism of drug release. Table 9
shows an analysis of diffusional release mechanism obtained by various value of n.
The criteria for selecting the most appropriate model were chosen on the basis of
goodness of fit test. The data were processed for regression analysis using MS
EXCEL statistical function.
4.8.2.9 Biodegradability studies of floating tablet
The biodegradability studies were carried out using USP rotating basket appara-
tus. A tablet (50 mg) were introduced into the baskets which were rotated at 50 rpm
in 900 ml of different pH buffer solution (5.0, 6.8, 8.0) maintained at 37°C  0.5°C.
4.8.2.10 Stability studies
To assess the drug and formulation stability, stability studies were done
according to ICH guidelines. The promising formulation F4 was tested for acceler-
ated testing for a period of 2 months at 40°C  2°C/ 75% RH 5% for their drug
content and other parameters.
S. No n value Mechanism
1 n ≤ 0.5 Quasi-fickian diffusion
2 0.5 Fickian diffusion
3 0.5 ≥ n ≤ 1.0 Anomalous (non-fickian) diffusion
4 n ≥ 1.0 Non-fickian super case 11
5 1 Non-fickian case 11
Table 9.
Release mechanism with variation of n values.
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5. Result and discussion
The effervescent floating tablets of SDs of DS were formulated in 6 different
batches F1 to F6 by using hydrophilic polymers HPMC K4M, HPMC K15M and
hydrophobic polymer carbopol 934P along with effervescing agents, sodium bicar-
bonate and citric acid (Table 8). All the formulations were prepared by wet granu-
lation method. In order to get the longer duration of floating time the high viscosity
polymer selected, HPMC K4Mwas chosen and it was found that, increased viscosity
of a polymer prolongs the drug delivery from the dosage form. IR study was carried
out to check the compatibility between the selected polymers with the diclofenac
sodium drug. This study was performed to assure that there is complete physical
entrapment of the drug into the polymer matrix without any mutual interaction. IR
spectra were taken for samples like pure drug, and drug-polymer physical mixture
at a wavelength of between 4000 and 400 cm1. All the spectra were compared for
shifting of major functional peaks and also for the loss of functional peaks for
identification of incompatibility, if any. When the spectra were compared it was
found that there was no shifting of functional peaks and no overlapping of charac-
teristic peaks and also there was no appearance of new peaks. Figures 2, 7 and 8
shows the IR spectra of various samples. No significant change in the IR spectra of
diclofenac sodium complexes was obtained, except for the broadening of the peaks.
The broadening of peaks may be probably due to the restriction of bending and
stretching vibrations of the molecule [6]. The preformulation studies such as angle
of repose, bulk density, tapped density, and carr’s index evaluated were found to be
within prescribed limits and indicated good free flowing property (Table 10).
In vitro Buoyancy of all the prepared tablets formulations were determined using
100 ml beaker containing 0.1NHCl medium shown in (Table 11) and the results can
be concluded that the batch F3 containing HPMCK4M and carbopol 934P in higher
concentration showed good buoyancy lag time is 4.3 min and total floating time is
15 hrs. TFT depends upon the amount of HPMC as the polymer content increased
the floating time was increased due to the formation of thick gel which entrapped
the gas formed due to NaHCO3 firmly. Among these formulations, the in vitro
buoyancy was increased in the following order: F3 > F1 > F4 > F2 > F5 > F6. The
Table 9 revealed that FLT minimum for F3 formulation, while its TFT was maxi-
mum i.e. 24 h; hence, F3 was selected for further evaluations and in vitro drug
dissolution studies.
Formulation F3 was evaluated for physical characters like tablet thickness,
diameter, hardness, friability, weight variation, percent swelling index, in vitro drug
release studies. The thickness, diameter and hardness of the formulations satisfied
the acceptance criteria. The friability and weight variation was found to be within
the limits specified in pharmacopoeia. The drug content was found
Parameter F1 F2 F3 F4 F5 F6
Angle of
repose
22.53° 22.17° 23.42° 21.57° 22.87° 23.34°
Bulk
density
0.953  0.026 0.948  0.031 0.975  0.0.098 0.881  0.102 0.836  0.057 0.899  0.083
Tapped
density
1.05  0.011 1.041  0.019 1.031  0.026 0.978  0.020 0.981  0.017 0.969  0.038
Carr’s index 7.64  0.94 6.66  0.71 5.69  0.56 8.99  0.62 8.68  0.83 7.97  0.49
Table 10.
Pre-compression parameters of granules.
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spectrophotometrically indicating good content uniformity in the prepared formu-
lation results were shown in Table 12.
The swelling index was calculated with respect to time. As time increase, the
swelling index was increased because weight gain by tablet was increased propor-
tionally with rate of hydration. The direct relationship was observed in Table 13.
The floating formulation F3 was subjected for the dissolution studies using USP
type II apparatus with wire sinker in 900 ml of 0.1 N HCl medium. The results are
given in Table 14. The formulation showed a constant rate of release in a sustained
manner similar to zero order kinetics with good buoyancy property. Diclofenac
sodium effervescent floating controlled release tablet formulation using solid dis-
persion (F3) showed far better release than marketed products.
5.1 Effect of sodium bicarbonate concentration on lag time of tablets
The concentration of sodium bicarbonate was found to be critical factor that
influenced buoyancy of tablets (Table 15). Sodium bicarbonate released CO2 gas
that was trapped into the polymeric matrix of HPMC that made the tablets float.
Various concentrations of sodium bicarbonate ranging from 5–12% of tablet weight
were used. From the results, it was concluded that with the increasing
Parameter F1 F2 F3 F4 F5 F6
Floating lag time (FLT) (s) 160 182 158 163 221 223
Total Floating time (TFT) (h) 22 21 24 20 24 21
Table 11.













F1 4.3  0.016 4.8  0.4 0.24  0.08 542.4  1.9 99.86  0.15
F2 4.4  0.013 5.1  0.3 0.51  0.03 555.8  1.5 99.45  0.08
F3 4.5  0.015 5.4  0.6 0.17  0.04 554.3  1.1 100.01  0.04
F4 4.5  0.013 4.9  0.4 0.46  0.03 545.1  1.8 99.96  0.18
F5 5.5  0.014 4.4  0.1 0.35  0.05 649.1  1.7 98.90  1.05
F6 5.7  0.011 5.8  0.3 0.41  0.04 647.3  0.4 99.02  0.01
Table 12.
General characteristic of floating tablets.
% Swelling index (percentage water uptake)








% Swelling index (percentage water uptake) of floating tablets.
17
Preparation and in vitro Characterisation of Solid Dispersion Floating Tablet…
DOI: http://dx.doi.org/10.5772/intechopen.92187
concentration of sodium bicarbonate, the lag time decreased. A concentration of
8.5–9% w/w sodium bicarbonate was found to be optimal that resulted in tablets
having lag time < 3 min and floating time of over 12 h. Similar conclusions were
also drawn by other researchers working on floating delivery systems. In both the
reported works, optimum concentration of sodium bicarbonate was found to be
























0 0 0.00 0.00 0.000 0.000
15 15.25  0.64 21.23  0.61 30.51  0.54 12.706  0.67 15.266  0.41
30 37.37  0.53 39.44  0.64 52.25  0.49 16.258  1.27 18.365  0.38
60 51.77  0.86 70.76  0.58 92.99  0.78 19.353  0.98 26.548  0.51
90 24.930  0.79 27.897  0.50
120 27.966  0.93 31.377  0.43
150 32.220  0.76 38.323  0.45
180 38.922  1.22 45.233  0.29
210 45.875  0.96 54.320  0.27
240 51.519  1.23 61.522  0.30
270 60.865  1.31 64.267  0.31
300 64.037  .55 69.613  0.35
330 68.561  1.53 73.670  0.51
360 73.686  0.77 76.568  0.42
390 77.371  1.16 80.179  0.44
420 82.957  0.98 85.363  0.47
450 86.414  0.74 87.573  0.58
480 89.213  1.78 96.769  1.19
Table 14.
Comparative in vitro release study of marketed tablets, physical mixture, solid dispersion and floating tablets
of diclofenac solid dispersion.










Comparison of floating lag time prepared from concentration of sodium bicarbonate.
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5.2 Effect of HPMC grade on lag time of tablets
It was interesting to note that the grade and quantity of HPMC used in the
formulations has impact on floating lag time of the tablet. With the increasing
molecular weight/quantity of HPMC, the viscosities of the gel matrix around the
tablet also increased which in turn in- creased the floating lag time. The lag time for
HPMC K15M tablets was slightly higher compared to HPMC K4M tablet. This may
be attributed to the increased density of tablet with increasing molecular weight of
HPMC (Table 16).
5.3 Kinetic of drug release
The various release kinetic models (Figures 9–12) were applied to determine the
mechanism of drug release from gastro retentive floating tablets and the data is
tabulated in Table 17. The in vitro drug release of optimised formulation (F3)
showed the highest regression coefficient values for zero order model, thus indicat-
ing absolute correlation between the two variables for the zero order model.
Optimised formulations followed Zero order equation proving that the release is by
diffusion mechanism. The values of release exponent (n) were calculated from
korsmeyer and peppas equation and the ‘n’ value was determined to be 0.5665
indicating Anomalous (non-fickian) diffusion.
So it can be conclude that the optimised formulation follows the zero order plot
to a major extend along with other plots to some extent.
S. No. Quantity of HPMC (mg) Floating lag time (s)
1 70 (HPMC K4M) 160
2 93 (HPMC K4M) 158
3 105 (HPMC K4M) 163
4 70 (HPMC K15M) 182
5 93 (HPMC K15M) 221
6 105 (HPMC K15M) 223
Table 16.
Comparison of floating lag time prepared from different grade or quantity of HPMC.
Figure 9.
Zero order release kinetics of optimised formulation.
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Figure 10.
First order release kinetics of optimised formulation.
Figure 11.
Higuchi kinetics of optimised formulation.
Figure 12.
Korsmeyer-Peppas kinetics of optimised formulation.
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5.4 Biodegradability studies of floating tablet
Biodegradability studies revealed that the gastro retentive floating tablet of
diclofenac (F3) was found to disintegrate and dissolve in intestinal pH within 3 h
(Figure 13).
Formulation F3 seemed to completely biodegrade in intestinal fluid, and it is the
pH of media, which is responsible for slow dissolution of the tablet in intestinal
fluid. This indicates that after gastric emptying the regular shaped tablet, gradually
become rough with an irregular surface and thereafter was degraded. Thus the
gastro retentive floating tablets of diclofenac proved to be suitable gastro retentive
dosage form, as they have a rigid structure that resist biodegradation in gastric pH
but exhibit complete biodegradation in phosphate buffer pH 8.0.
5.5 Stability studies
Pharmaceutical dosage forms are complex systems composed not only of drug
substances but also of various excipients. These excipients, which are non-
therapeutic, are intended to contribute desirable, practical properties to the dosage
form. These dosage forms may undergo both chemical and physical degradation
[28]. Thus, the success of the effective formulation can be evaluated only through
the stability studies. This study pursues two particular aims:
• Determination of the optimum formulation and shelf life during
developmental stages.
• Derivation of the stability of a product, which guarantees the safety and
efficacy of the product up to end of the shelf life at a defined storage condition
and pack profile.
So, stability of a pharmaceutical product may be defined as the capability of a
particular formulation in a specific container, to remain in its physical, chemical,
microbiological, therapeutic and toxicological specifications. Ability of a
S.No Formulation Zero order First order Higuchi Korsmeyer-peppas
1 F3 K R2 K R2 K R2 N R2
10.373 0.9882 0.1373 0.8541 0.3444 0.9837 0.5665 0.9616
Table 17.
Release kinetic equation values of the optimised formulations.
Figure 13.
Images of complete biodegradation of F3 floating tablet after 3 h.
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formulation to retain properties in specified limits throughout its shelf-life is
referred as stability [28].
The stability of finished pharmaceutical products depends on several factors. On
the one hand, it depends on environmental factors such as ambient temperature,
humidity and light. On the other hand, it depends on product related factors such as
chemical and physical properties of active substance and pharmaceutical excipients,
the dosage form and its composition, the manufacturing process, the nature of
container closure system and properties of packaging materials.
A study of stability of a pharmaceutical product is essential for safety of the
patients, legal requirements concerned with the identity, strength, purity and
quality of the drug and to prevent the economic repercussions of marketing an
unsuitable product [29, 30].
5.5.1 Experimental
Optimised formulations were stored in screw capped small glass bottles at room
temperature and in stability chamber at 40  1°C and 75% relative humidity.
Samples were analysed for physical appearance, Hardness (kg/cm2), Friability (%),
Uniformity of weight (mg), Drug content (%), Thickness (mm), Buoyancy lag time
(s), Floating time (h) and in vitro release after a period of 15, 30, 45, 60, 75, 90 days.
Initial drug content was taken as 100% for each formulation. Observations are
recorded in Tables 18 and 19.
5.5.1.1 Physical characteristics
Various physical parameters were evaluated such as appearance, Buoyancy lag
time (s), floating time. Observations are recorded in Table 18.
S. No. Physical parameters 0 days 15th days 30th days 60th days 90th days
1 Appearance + + + + +
2 Floating time + + + + +
3 Buoyancy lag time (s) + + + + +
+, no change.
Table 18.
Effect of ageing on physical parameters.
Parameter Optimised formulation (F3) (n = 3)
At 0 day At 15 days At 30 days At 60 days
Hardness (kg/cm2) 5.4  0.08 5.4  0.1 5.4  0.09 5.2  0.07
Friability (%) 0.17  0.02 0.17  0.01 0.19  0.02 0.20  0.01
Uniformity of weight (mg) 554.3  1.1 554.3  1.1 554.3  1.1 554.3  1.1
Drug content (%) 100.01  0.04 100.01  0.04 99.50  0.58 98.89  0.12
Thickness (mm) 4.55  0.12 4.55  0.09 4.55  0.10 4.55  0.11
Table 19.




Various parameters were evaluated such as Hardness (kg/cm2), Friability (%),
Uniformity of weight (mg), Drug content (%), Thickness (mm), and in vitro release
after a period of 15, 30, 45, 60, 75, 90 days. Observations are recorded in Table 19.
5.5.1.3 Drug content was assayed by U.V. spectrophotometry
Gastro retentive floating tablet of diclofenac sodium (50 mg) was dissolved in
100 ml of 0.1 N HCl (pH 1.2) by stirring for 6 h using magnetic stirrer. The resulting
solution was then filtered using 0.45 m millipore filter, 1 ml of this solution was
taken and added to 100 ml of 0.1 N HCl (pH 1.2). It was then analysed spectropho-
tometrically at the predetermined λ max (276 nm) to determine concentration of
the drug. The determinations were made in triplicate.
5.5.1.4 In vitro dissolution studies
In vitro dissolution studies were carried out using simulated gastric fluid
(pH 1.2).
5.5.2 Result and discussion
5.5.2.1 Physical parameters of the optimised tablets formulation
The Physical parameters after 15th, 30th, 60th, 90th days are as mentioned in
Table 18. All the Physical parameter are within the acceptable limits which indi-
cated that gastro retentive floating tablet of diclofenac sodium showed no signifi-
cant change in the physical appearance at room temperature and in stability
chamber at 40°C  2°C and 75  5% relative humidity indicating that the formula-
tions were physically stable at these temperatures.
5.5.2.2 Physico-chemical parameters of the optimised formulation
Various parameters were evaluated such as Hardness (kg/cm2), Friability (%),
Uniformity of weight (mg), Drug content (%), Thickness (mm), and in vitro release
S. No. Sampling interval (days) % Residual drug content
Mean  S.D. (n = 3)
At room temp. At 40  2°C/75  5% RH
1 0 100.01  0.03 100.01  0.03
2 15 99.82  0.12 99.66  0.09
3 30 99.56  0.09 99.25  0.18
4 45 98.75  0.14 98.40  0.15
5 60 98.56  0.05 97.72  0.9
6 75 98.07  0.09 97.51  0.10
7 90 97.69  0.07 96.66  0.06
Table 20.
Effect of ageing on residual drug content at room temperature &40  2 °C/ 75  5%RH.
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after a period of 15, 30, 45, 60, 75, 90 days. Observations are recorded in Table 6.
All the physico-chemical parameters are within the acceptable limits which
indicated that formulation were stable over the period of 90 days.
5.5.2.3 Residual drug content of stability batch
Initial drug content of formulations was 100.01  0.04.the drug contents at the
end of 15th, 30th, 60th, 90th days were found to be as given in Table 20. The
drug content was within the permissible limits. The percent residual drug content
was determined and the log percent residual content was plotted against time t
(Figures 14–17), which reflected almost linear relationship.
5.5.2.4 In vitro dissolution studies
The dissolution results obtained were as given in the Table 21.
The dissolution behaviour of samples withdrawn at different interval was similar
and the difference in dissolution pattern of samples kept at two different conditions
of storage was negligible.
The log % residual drug content vs. time graph was also plotted in order to
evaluate shelf-life and half-life of formulations.
Figure 14.
Effect of ageing on residual drug content at 40  2°C/75  5%RH.
Figure 15.
Plot of log % residual drug content Vs time at 40  2°C/75  5%RH.
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Shelf-life was evaluated by the equation:
T10% ¼ 0:104=K (9)
Degradation rate constant K was calculated from the slope of straight line
between log of % residual drug and time interval. The time required for degradation
of 10% drug was calculated as T10%.
Figure 17.
Plot of log % residual drug content vs. time at room temp.
Figure 16.
Effect of ageing on residual drug content at room temperature.
Time interval (days) % Cumulative drug release in 8 h  SD (n = 3)
Room temperature 40  2°C/75  5% RH
0 96.769  1.19 96.769  1.19
15 95.78  0.84 94.34  1.52
30 94.81  1.64 93.05  0.81
60 94.45  0.56 92.89  0.69
90 93.97  0.93 92.45  1.21
Table 21.
Effect of ageing on % cumulative drug release at room temperature & 40  2°C/75  5%RH.
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Half-life was evaluated by the equation:
T1=2 ¼ 0:693=K (10)
Gastro retentive floating tablet of diclofenac sodium stored at 40  2°C/75  5%
RH showed K value as 3.822  104 and t10% value as 272.039 days, while those
stored at room temperature showed K value as 2.303  104 and t10% value as
451.58 days (Table 22).
The T10% obtained in case of formulation stored at 40°C  2°C/75  5%RH was
found to be lower in comparison with the formulation stored at room temperature
which indicated that the formulations tend to degrade faster at higher temperatures
and humidity.
The results of stability studies suggest that for adequate shelf life of optimised
gastro retentive floating tablet of diclofenac sodium, it should be stored in cool and
dry place.
6. Conclusions
In the above research work, ECRFT has been developed by using dual approach;
one is solid dispersion (for solubility enhancement) and other is effervescent float-
ing technique (for achieving extended retention in upper G.I.T.), which was pre-
pared from previously optimised solid dispersion of diclofenac sodium. Formulated
tablets showed outstanding physicochemical properties, biodegradation studies,
stabilities studies, and prolong gastric retention with control release. When com-
pared with marketed tablets of immediate release (Voveran-50) and control release
(Voveran-100SR), the optimised formulation F3 was found to be favourable for
improving bioavailability of drug, enhancing its therapeutics efficacy and improv-
ing patient compliance due to less frequent dosing requirement. Hence, it can be
concluded that the prepared formulation can be used positively as a particular oral
controlled release-floating tablet for once a day administration.
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SEM scanning electron microscopy
PM physical mixtures
DT disintegration time




TBD tapped bulk density
TFT total floating time
%WU percentage water uptake
FLT floating lag time
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